Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.04 - $6.37 $451,752 - $712,293
-111,820 Reduced 72.07%
43,338 $202,000
Q1 2024

May 15, 2024

SELL
$2.25 - $7.4 $294,387 - $968,208
-130,839 Reduced 45.75%
155,158 $1.06 Million
Q4 2023

Feb 14, 2024

BUY
$1.84 - $3.35 $398,628 - $725,764
216,646 Added 312.39%
285,997 $958,000
Q3 2023

Nov 14, 2023

BUY
$1.26 - $2.77 $56,444 - $124,087
44,797 Added 182.44%
69,351 $172,000
Q2 2023

Aug 14, 2023

SELL
$0.77 - $1.8 $49,738 - $116,271
-64,595 Reduced 72.46%
24,554 $31,000
Q1 2023

May 15, 2023

SELL
$0.75 - $1.21 $66,468 - $107,235
-88,624 Reduced 49.85%
89,149 $72,000
Q4 2022

Feb 14, 2023

SELL
$0.54 - $1.12 $2,067 - $4,287
-3,828 Reduced 2.11%
177,773 $135,000
Q3 2022

Nov 14, 2022

BUY
$0.86 - $1.55 $2,881 - $5,192
3,350 Added 1.88%
181,601 $169,000
Q2 2022

Aug 15, 2022

SELL
$0.76 - $2.64 $77,536 - $269,338
-102,022 Reduced 36.4%
178,251 $169,000
Q1 2022

May 16, 2022

BUY
$1.48 - $6.22 $372,726 - $1.57 Million
251,842 Added 885.8%
280,273 $591,000
Q4 2021

Feb 14, 2022

SELL
$8.77 - $18.29 $6,165 - $12,857
-703 Reduced 2.41%
28,431 $254,000
Q3 2021

Nov 15, 2021

BUY
$13.54 - $22.06 $252,426 - $411,264
18,643 Added 177.7%
29,134 $484,000
Q2 2021

Aug 16, 2021

BUY
$14.05 - $25.04 $147,398 - $262,694
10,491 New
10,491 $218,000
Q4 2020

Feb 16, 2021

SELL
$15.44 - $24.23 $422,484 - $663,005
-27,363 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$19.43 - $35.36 $531,663 - $967,555
27,363 New
27,363 $568,000
Q2 2020

Aug 14, 2020

SELL
$29.41 - $51.23 $230,397 - $401,335
-7,834 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$19.54 - $55.47 $153,076 - $434,551
7,834 New
7,834 $256,000

Others Institutions Holding APLT

About Applied Therapeutics Inc.


  • Ticker APLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,700
  • Market Cap $42.3M
  • Description
  • Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...
More about APLT
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.